ClinicalTrials.gg
RecruitingNCT07023172Updated Feb 5, 2026

Multicenter, Prospective, Observational Study on the Treatment of Type 2 Diabetes With Proline Plus Empagliflozin Tablets

An observational study in Type 2 Diabetes, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Diabetes Mellitus, Type 2 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School — 11 open to participants now, 12 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.

Started
2025
with 3 others
Observational
7 of 19
6 open now
Primary completion
2027-10
later than 5 of 11 live
Registered
13th of 19
by date

Among the 19 studies in Diabetes Mellitus, Type 2 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, this one is one of 4 that started in 2025, is one of 7 observational ones, reaches primary completion later than 5 of the 11 other live ones, and was the 13th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

11 of the 19 studies in Diabetes Mellitus, Type 2 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Diabetes Mellitus, Type 2 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, or all of them as a file.
02

Study summary

This study is a post-marketing, multicenter, prospective, observational study designed to evaluate the efficacy and safety of Proline Plus Empagliflozin Tablets in the real-world clinical treatment of type 2 diabetes mellitus. The study does not interfere with routine clinical practice, and Proline Plus Empagliflozin Tablets may be used either as monotherapy or in combination with other therapeutic agents based on actual clinical needs.

Read the detailed description

This study is a post-marketing study aimed at evaluating the effectiveness and safety of proline-containing gliflozin tablets in the real-world clinical treatment of type 2 diabetes mellitus. The study is designed as a multicenter, prospective, observational study. This research does not interfere with clinical diagnosis and treatment, and proline-containing gliflozin tablets may be used as monotherapy or in combination with other therapeutic drugs based on actual needs.

Dosage and administration of proline-containing gliflozin tablets:

For newly diagnosed type 2 diabetes patients: The initial dose is one tablet once daily, taken with meals. For patients requiring enhanced glycemic control who tolerate 25 mg once daily, the dose may be increased to 50 mg once daily, taken with meals.

This study includes a screening period (D-14 to D0) and a treatment period (12 weeks ± 7 days, 24 weeks ± 28 days, 48 weeks ± 28 days), totaling 4 visit points. During the study, patients may undergo examinations based on actual clinical needs. The trial requires recording patients' baseline physical examinations, study drug prescription and concomitant medication use, examinations performed according to clinical needs, and the occurrence of adverse events or adverse drug reactions.

The EQ-5D score will be assessed for all subjects. Additionally, for subjects aged 50 years or older (with an education level of elementary school or above), the MoCA (Version 7.1) score and cognitive impairment assessment will be conducted at all visit points except the second one.

Subgroups will be defined based on baseline age (\<65 years, ≥65 years), HbA1c (HbA1c ≥7%, ≥9%, or ≥11%), BMI (BMI \<24.0 kg/m², 24.0 kg/m² ≤ BMI ≤ 28.0 kg/m², BMI ≥28.0 kg/m²), and concomitant medications (number and types of glucose-lowering drugs) to observe differences in efficacy between subgroups.Subgroups will also be defined based on comorbidities to observe the glucose-lowering efficacy and changes in relevant clinical indicators in different comorbidity populations, such as:Chronic kidney disease population: Focus on changes in serum creatinine (SCr), urine protein (Pro), estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (UACR), and major adverse kidney events (MAKE).Cardiovascular disease population: Focus on major adverse cardiovascular events (MACE) and echocardiographic indicators.

Retinopathy population: Focus on fundus examination results.Cognitive impairment population: Focus on changes in MoCA scores.The analysis indicators will be based on actual analyzable data generated during the study.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Type 2 diabetes
  • Proline plus empagliflozin tablets
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Age ≥18 years, no gender restriction; clinically diagnosed with type 2 diabetes mellitus (per Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus [2020]); deemed by investigators as suitable for and initiating empagliflozin treatment for the first time.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Age ≥18 years, regardless of gender. 2.Clinically diagnosed with type 2 diabetes mellitus (per the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus [2020 Edition]).

    3.Deemed suitable by the investigator for treatment with proline-containing gliflozin tablets (Hui You Jing) and being prescribed this medication for the first time.

    4.Availability of (HbA1c) test results within 4 weeks prior to enrollment.

    5.Voluntary participation with signed .

Exclusion criteria

Exclusion Criteria:

- 1.History of moderate to severe renal impairment ( \<30 mL/min/1.73 m²), end-stage renal disease, or dialysis.

2.Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Severe allergy to gliflozin or any of the study drug. 3.Current or recent (within 1 month) participation in any other clinical trial. 4.Investigator judgment of unsuitability for the study.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. HbA1c <7.0%

    Glycemic control rate at 24 weeks, where glycemic control is defined as HbA1c \<7.0%

    Time frame: at 24 weeks

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Oct 2027, 29 months after the start.

Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 29 months is below that.

Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 15, 2025
StartActual
May 30, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07023172
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
May 30, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Feb 5, 2026

Study contacts

Bi Yan
Contact
biyan@nju.edu.cn
86+13655176388
Ge Zhi Juan
Contact
gzjyunduan@126.com
86+18061758651

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion